scispace - formally typeset
S

Serpil C. Erzurum

Researcher at Cleveland Clinic Lerner Research Institute

Publications -  406
Citations -  34734

Serpil C. Erzurum is an academic researcher from Cleveland Clinic Lerner Research Institute. The author has contributed to research in topics: Asthma & Medicine. The author has an hindex of 87, co-authored 353 publications receiving 29654 citations. Previous affiliations of Serpil C. Erzurum include Pulmonary Vascular Research Institute & National Institutes of Health.

Papers
More filters
Journal ArticleDOI

Redox control of asthma: molecular mechanisms and therapeutic opportunities.

TL;DR: Monitoring of exhaled (*)NO has entered clinical practice because it is useful to optimize asthma care, and a wide array of other biochemical oxidative and nitrative biomarkers are currently being evaluated for asthma monitoring and phenotyping.
Journal ArticleDOI

Rapid loss of superoxide dismutase activity during antigen-induced asthmatic response

TL;DR: Reduction of superoxide dismutase activity within minutes of an acute asthmatic response to segmental antigen instillation into the lung of individuals with atopic asthma suggests that enrichment of lung antioxidants is therapeutic for asthma.
Journal ArticleDOI

Oxidation increases mucin polymer cross-links to stiffen airway mucus gels.

TL;DR: These findings support the use of mucolytics as a therapeutic strategy for CF and related inflammatory lung diseases and suggest that oxidation arising from airway inflammation or environmental exposure contributes to pathologic mucus gel formation in the lung, which suggests that it can be targeted by thiol-modified carbohydrates.
Journal ArticleDOI

Oxidative Stress in Asthma

TL;DR: The current knowledge is summarized and the current and future strategies for the modulation of oxidative stress in asthma are discussed.
Journal ArticleDOI

Interferon gamma and interleukin 4 stimulate prolonged expression of inducible nitric oxide synthase in human airway epithelium through synthesis of soluble mediators.

TL;DR: A combination of IFNgamma/ IL-4, which occurs naturally in the lung epithelial lining fluid, leads to maintenance of iNOS expression in human airway epithelium through production of soluble mediators and stabilization of mRNA.